Enrollment Milestone Achieved in Hansa Biopharma’s Pioneering Imlifidase Phase 2 Study for Guillain-Barré Syndrome
Hansa Biopharma (Nasdaq Stockholm: HNSA), an innovative frontrunner in enzyme technology dedicated to addressing rare immunological disorders, is pleased to...